

Jennifer B Green

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7165586/publications.pdf>

Version: 2024-02-01

60
papers

5,765
citations

218592

26
h-index

133188

59
g-index

62
all docs

62
docs citations

62
times ranked

5997
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline Development for Medical Device Technology: Issues for Consideration. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1698-1710.	1.3	2
2	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
4	Use of Lipid-, Blood Pressure, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e2148030.	2.8	30
5	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
6	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1849-1857.	1.2	34
7	Validation of the WATCH-DM and TRS-HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	10
8	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 1670-1690.	4.3	109
9	Roles for SGLT2 Inhibitors in Cardiorenal Disease. <i>CardioRenal Medicine</i> , 2022, 12, 81-93.	0.7	5
10	Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e016835.	1.6	31
11	Cardiovascular Consequences of Gestational Diabetes. <i>Circulation</i> , 2021, 143, 988-990.	1.6	9
12	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
13	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	2.8	5
14	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	1.1	4
15	The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy—the GRADE study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108047.	1.2	3
16	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	1.2	48
17	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	1.2	45
18	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 220, 82-88.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the <sc>TECOS</sc> randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2026-2034.	2.9	18
20	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
21	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108235.	1.1	20
22	BARI 2D: A Reanalysis Focusing on Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2249-2262.	1.4	3
23	Associations between β -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 92-99.	1.2	4
24	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	0.7	18
25	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4
26	Heart Failure With Preserved Ejection Fraction and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 602-611.	1.2	182
27	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> 2019;42:157-163. <i>Diabetes Care</i> , 2019, 42, e95-e95.	4.3	0
28	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 58-62.	0.8	2
29	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
30	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
31	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	4.3	59
32	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	2.2	5
33	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	6.3	1,179
34	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
35	Preventing Heart Failure in Diabetes. <i>JACC: Heart Failure</i> , 2018, 6, 831-832.	1.9	0
36	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2379-2388.	2.2	29

#	ARTICLE	IF	CITATIONS
37	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
38	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
39	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , 2017, 40, 494-501.	4.3	50
40	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
41	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	4.3	60
42	The potential role and rationale for treatment of heart failure with sodiumâ€”glucose coâ€”transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
43	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
44	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 67.	1.7	4
45	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
46	Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e121-e128.	2.2	60
47	Sitagliptin and risk of fractures in type 2 diabetes: <scp>R</scp>esults from the <scp>TECOS</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 78-86.	2.2	52
48	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	4.3	49
49	Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?. <i>PLoS ONE</i> , 2016, 11, e0156068.	1.1	9
50	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
51	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	13.9	2,188
52	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015, 28, 995-1009.	1.0	18
53	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
54	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. <i>Postgraduate Medicine</i> , 2014, 126, 190-204.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Diabetes trials: is an ounce of prevention enough?. Expert Review of Endocrinology and Metabolism, 2013, 8, 419-421.	1.2	0
56	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal, 2013, 166, 983-989.e7.	1.2	116
57	The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety. Postgraduate Medicine, 2012, 124, 54-61.	0.9	12
58	New combination treatments in the management of diabetes: focus on sitagliptin – metformin. Vascular Health and Risk Management, 2008, Volume 4, 743-751.	1.0	39
59	Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity. Current Diabetes Reports, 2007, 7, 369-375.	1.7	6
60	Are sulfonylureas passÃ©?. Current Diabetes Reports, 2006, 6, 373-377.	1.7	20